Staff Scientist, Vascular Biology Program, Boston Children's Hospital
Instructor, Harvard Medical School
Andreane did her PhD in the lab of Dr. Jean-Luc Parent in Sherbrooke, Quebec, where she studied the interaction between WDR36 and thromboxane A2 receptor (TPβ), and its impact on downstream signaling. Her training with Dr. Timothy Hla gives her the opportunity to apply her knowledge of GPCR signaling, molecular biology and transcriptional gene regulation to different mice models. She first published her work with Dr. Hla on the role of endothelial S1P receptors in tumor angiogenesis, tumor growth and anti-tumor therapy efficacy. She also performed a Whole Genome siRNA Screen to identify new targets of the endocytic pathway of S1PR1 induced by Fingolimod, a synthetic functional antagonist of S1PR1 and FDA approved molecule, currently used as a treatment for multiple sclerosis.
She is interested in the role of S1PR1 and S1PR2 in vascular dysfunction caused by a chronic inflammatory environment in vitro and in vivo, and how the imbalance of these two receptors leads to endothelial dysfunction and vascular injury, key processes in cardiovascular disease development.
Publications Highlights
Brazee PL, Cartier A, Kuo A, Haring AM, Nguyen T, Hariri LP, Griffith JW, Hla T, Medoff BD, Knipe RS. Augmentation of Endothelial S1PR1 Attenuates Post-Viral Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2023
Cartier A, Leigh T, Liu CH, Hla T. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci U S A. 2020
Cartier A, Hla T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019
Email: Andreane.Cartier@childrens.harvard.edu
Phone: (617) 919-2404
Phone: (617) 919-2404